A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

NCT07803744 · Not yet recruiting

Last updated 2026-09-22

This study tests how the drug tirzepatide is absorbed in people with type 1 diabetes who are also overweight or obese.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 18 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2026-09 · est. completion 2026-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07803744 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC.
Acetaminophen Drug

Administered orally.
Placebo Drug

Administered SC.

Main thing measured	Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 1, Overweight, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07803744 ↗